The postoperative outcomes of the dominant lung adenocarcinoma with multiple synchronous ground glass nodules.
Subject Areas

*Cardiothoracic Surgery*

Keywords

*multiple primary lung cancers, adenocarcinoma, ground glass opacity, ground glass nodule, surgical treatment*
Abstract

Background
Multiple synchronous ground glass nodules (GGNs) are known to be malignant but progress slowly. Multiple synchronous lesions in the same patient show independent characteristics and must be treated individually.

Methods
This was a retrospective review of 34 lung adenocarcinoma patients with multiple synchronous GGNs in an Asian population. One hundred twenty-seven single lung adenocarcinoma patients were included for comparison. The follow-up period was 5 years for all patients.

Results
The 5-year overall survival (OS) patients with multiples did not differ from that of patients with single lesion to a statistically significant extent (Single: 81.8% vs. Multiple: 88.2%, P = 0.3602). Dominant tumors (DTs) with a ground glass component and consolidation were divided into three categories based on the consolidation-to-tumor ratio on radiological imaging. No significant differences were observed among the three DT categories. Twenty-four patients had unresected GGNs, progression of the unresected GGN occurred in 10 of these cases. The OS and disease-free survival (DFS) curves of patients with and without GGN progression did not differ to a statistically significant extent (OS: 80% vs. 92.9%, P = 0.3870; DFS: 80% vs. 100%, P = 0.0977).

Conclusions
The outcomes were best predicted by the stage of the DT. After surgery patients require careful follow-up because unresected GGNs may progress. At the same time, the increase in residual lesions and the appearance of new GGNs were not related to OS. The management should be determined by the DT with the worst prognosis.

Introduction
Low-dose computed tomography (CT) screening has led to a relative reduction in mortality from lung cancer (1), and an increase in the incidental diagnosis of small pulmonary ground glass nodules (GGNs) (2-5). New guidance on the management of GGN is required and has been proposed (6, 7). However, no standard algorithms have been established for multiple GGN detected by screening. Thus, there is a lack of clinical evidence on their natural history, diagnosis and treatment.

A number of studies have suggested that multiple GGNs have independent characteristics (8, 9). Next-generation sequencing has shown that some multiple synchronous lesions show different mutation profiles in the same patient, while others share identical gene mutations (10). These results suggest that the dominant tumor (DT) and synchronous GGN are genetically independent tumors. Evidence is emerging that—given the independent characteristics of each of the multiple GGNs in a patient—the management of multiple GGNs should be determined based on the DT that carries the worst prognosis (11, 12). Follow-up of the remaining lesions after the surgical treatment of the DT has been reported (13, 14). However, there no reports have compared the outcomes of patients with multiple GGNs to those of patients with single lesions. Furthermore, in cases of synchronous GGN, the postoperative outcomes were compared according to the progression of DT in order to investigate whether priority should be given to the DT when deciding the treatment strategy.

Patients And Methods
We retrospectively studied patients who were referred for surgery at Shimane University Hospital, from January 2009 to December 2013. Two hundred nine patients met the following criteria: (1) adenocarcinoma, and (2) pN0. Pre-operative CT scans were reviewed to identify synchronous GGNs. Thirty-nine patients had one or more lesions other than the DT. The DT was defined as the lung lesion of the largest diameter or the lesion that showed the most radiological invasiveness (margin of the nodule, pleural indentation, presence of a solid component).

DTs with a ground glass component and consolidation were divided into three categories based on the consolidation-to-tumor (C/T) ratio on radiological imaging: pure GGN (C/T ratio = 0), part solid (C/T ratio > 0 to < 1) and solid tumor (C/T ratio = 1). The following cases were excluded from analysis: (1) cases involving recurrent lung cancer or in which the outcome was unknown, (2) stable lung cancer cases for which CT data had not been obtained for 5 years after surgery (Fig. 1).

Lung cancers were staged in accordance with the seventh edition of the TNM Classification for Lung and Pleural Tumors. All patients were regularly evaluated by CT every 3 months for the first 2 years after surgery and every 6 months thereafter. Tegafur-uracil was selected as adjuvant treatment for T1b patients. Cisplatin-based adjuvant chemotherapy was selected for patients with stage II disease. Non-dominant GGNs that were followed were generally treated by either surgical resection or stereotactic radiotherapy (SRT), when they grew size with any solid component.

The patient and tumor characteristics were analyzed to identify factors associated with overall survival (OS), disease-free survival (DFS), and progression of GGN. OS was calculated from the date of surgery until either death from any cause or the date of last follow-up, with a minimum of 5 years of study inclusion. DFS was defined as survival without extrapulmonary metastasis, locoregional or distant recurrence, or GGN progression requiring intervention. GGN progression was defined as growth of a GGN, development of a new solid component in a pure GGN, or enlargement of a solid component in a part-solid GGN with stable total diameter. Considering the error due to CT slice thickness, growth was defined as an increase of ≥ 5 mm.

**Statistical analyses**

Statistical analyses were performed using the GraphPad Prism 7 software program (GraphPad Software, La Jolla, CA, USA). Qualitative variables were reported the frequency and percentage, while quantitative variables were reported as the mean and standard deviation. Comparisons between two groups were performed using the unpaired t-test for normally distributed data. OS and DFS were calculated from the date of surgery and estimated using a Kaplan-Meier analysis. P values of < 0.05 were considered to indicate statistical significance.

**Results**

**Patient characteristics**

The patient and surgical characteristics are summarized in Table 1. There were 161 patients (multiple GGN [n=34], pure GGN [n=17], part solid [n=40] and solid [n=70]). Five years of follow-up was completed in all cases. All patients were Asian. Combined resection of multiple lesions was performed for 23% of the patients in the multiple GGN group. Twenty percent of the patients underwent wedge resection alone. Chemotherapy was performed according to the DT tumor size (pStage). There were three patients with pStage IIa disease in the multiple GGN group who did not receive chemotherapy.

**Postoperative outcomes**

Table 2 lists the results of postoperative surveillance. There were 18 cases of postoperative recurrence (multiple [n=2], part solid [n=3], and solid [n=13]). Eleven of them were positive for epidermal growth factor receptor (EGFR) mutations. The OS decreased as the C/T ratio increased (pure GGN, 94.1%; part solid, 90%; solid, 74.3%; Table2).

Kaplan-Meier analyses (Figure 2A) were performed to compare the patients with multiple lesions to those with
single lesions; their survival did not differ to a statistically significant extent (single, 81.8% vs. multiple, 88.2%; P=0.3602). There when the outcomes were compared according to the DT classifications (Pure GGN, 94.1% vs. multiple GGN [pure], 100%; part solid, 90% vs. multiple GGN [part], 90%; solid, 74.3% vs. multiple GGN [solid]: 77.8%; Figure 2B-D). The DFS was similar to the OS (Figure 3).

**Characteristics of the DT and non-dominant GGNs in the multiple GGN group**

Characteristics of the DT and the non-dominant GGN are summarized in Table 3. As for non-dominant GGN, there were 2 cases with very large numbers of nodules (46 and 18) in the part solid group; these cases were excluded as outliers. Radiographically, the mean diameters of the DTs were as follows: Pure GGN, 8.6±4.6 mm; part solid, 21.7±11.6 mm; and solid, 36.8±11.2 mm. The mean diameters of the largest non-dominant GGN at presentation were as follows: pure GGN, 8.1±1.8 mm; part solid, 8.2±5.2 mm; and solid, 17.5±11.7 mm. The numbers of with non-dominant GGNs were as follows: pure GGN (range, 1-2), n=8; part solid (range, 1–7), n=38; and solid (range, 1-5), n=17. Four pure GGNs (50%), 19 part solid GGNs (50%) and 9 solid GGNs (53%) were identified in the contralateral lung to the DT. Some of the lesions in the lung lobe that differed from the DT could not be resected. Twenty-four patients had unresected GGNs. In 10 of these patients, progression was found in the unresected GGN (Figure 4). In 2 cases, additional surgery or SRT was performed to treat the unresected GGN. Most unresected GGNs were pure GGN and none had a C/T ratio of >0.5.

**Characteristics of the patients with GGN progression**

The characteristics of the patients with or without progression of GGN are summarized in Table 4. The mean size of the unresected GGNs in the any GGN progression group was predominantly larger than that in the other group (mean size, 10.3±5.2 mm vs. 6.5±4.3 mm, respectively P=0.0004). The OS curve of the cases with and without GGN progression did not differ to a statistically significant extent (80% vs. 92.9%, P=0.3870).

The transition of the size of the 38 unresected GGNs on CT is shown in Figure5A. Twelve GGNs fulfilled the growth condition. Among them, 10 GGNs showed a change in size changed within 3 years. It took four years for all lesions change in size. The tumors of the GGNs that changed in size were significantly larger than no growth tumors (mean size 11.7±5.8 mm vs. 6.9±3.8 mm, P=0.0003) Figure5B.

**Discussion**

In this study, we compared multifocal GGNs and single lesions. The number of GGNs had no impact on the OS. As in the case of single lesions, the OS changed according to the pStage. The increase in residual lesions and the appearance of new GGNs were not associated with the OS.

Several studies have reported similar results, showing that prolonged survival was generally achieved by anatomic resection of the DT and wedge resection of the accessible GGNs (11, 14, 15, 16). As for OS and DFS, our results were similar to those of several previous studies. The novelty of this study was that it directly compared the outcomes of patients with multiple GGNs to those of patients with single lesions. The DTs were divided into three categories based on the C/T ratio, and the OS and DFS graphs for multiple and single lesions overlapped. In patients with multiple GGNs, management should be determined based on the DT with the worst prognosis.

Regarding unresected GGNs, previous studies have shown that many lesions remained unchanged, but that a certain proportion increase in size. No relationship was found between the prognosis and progression of the unresected GGN in this study, which is in line with previous reports (15, 16). In order to reduce wasteful follow-up, we think that is necessary to screen patients and lesions that are likely to increase in size. In this study, we found that the larger unresected GGN tended to increase in size. As far as the lesion was concerned, we found that lesions that were larger in size were more likely to grow. In previous reports, the size of the DT and the proportion of the solid component were also associated with an increased risk of lesion growth (15, 16). When possible, resecting larger-sized lesions with the DT may be the most efficient approach.
Regarding the follow-up period, GGNs may take 3–4 years to begin to increase in size (17, 18, 19). The same period was considered to be necessary in this study. Patients should be followed up for the same period.

Adenocarcinoma with EGFR mutation is reported to be associated with a higher incidence of GGN in comparison to adenocarcinoma with wild-type EGFR (20). Many of the recurrent cases in this study had EGFR mutations. Even in early-stage lung cancer, if patients have GGN lesions, the EGFR gene mutation status should be investigated during follow-up. However, it is worth noting that there are many reports of cases in which genetic analyses revealed differences between the DT and synchronous GGNs (10).

The present study was associated with some limitations, including the biases associated with the lack of randomization, as well as the relatively small sample size and limited statistical power. We were unable to analyze the effect of the mutation status. The strength of this study was that it compared the outcomes of patients with multiple GGNs to those of patients with a single lesion. There were no differences between the groups with regard to the methods of treatment and follow-up, and it was considered to be appropriate as a comparative group.

**Conclusions**

The postoperative outcome of lung adenocarcinoma with synchronous GGN was good.

The outcomes were best predicted by the stage of the DT. After surgery, patients require careful follow-up because unresected GGNs grow in size. At the same time, it is also true that many patients may not require follow-up.

**Abbreviations**

CT; computed tomography, GGNs; ground glass nodules, DT; Dominant tumor, OS; overall survival, DFS; Disease-free survival, C/T; consolidation-to-tumor, SRT; stereotactic radiotherapy, EGFR; epidermal growth factor receptor.

**Declarations**

**Ethics approval and consent to participate**

This study conforms to the ethical guidelines in a priori approval by the local Ethical Committee of the Shimane University. Our research was approved by the Shimane University Research Ethics committee (approval number: 3672, approval date: April 23, 2019).

**Consent for publication**

This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. All the authors have approved the manuscript and agree with submission to your esteemed journal.

**Availability of data and materials**

Not applicable.

**Competing interests**

The authors have no competing interests to disclose.
Funding

No funding was obtained for this manuscript.

Authors' contributions

Conception and design: TH, YT. Information Acquisition: TH, AT, MN, YA, MH, SH, KK. Drafting of Manuscript: TH, YT, MN, YA, MH, SH, KK, TI. Critical Review: YT, TI. The authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
2. Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91.
3. Zhao SJ, Wu N. Early detection of lung cancer: Low-dose computed tomography screening in China. Thoracic Cancer. 2015;6:385–9.
4. Nawa T, Nakagawa T, Mizoue T, et al. Low-dose Computed Tomography Screening in Japan. J Thorac Imaging. 2015;30:108–14.
5. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax. 2017;72:48–56.
6. Sihoe AD, Cardillo G. Solitary pulmonary ground-glass opacity: is it time for new surgical guidelines? Eur J Cardiothorac Surg. 2017;52:848–51.
7. Lococo F, Cusumano G, De Filippis AF, et al. Current Practices in the Management of Pulmonary Ground-Glass Opacities: A Survey of SICT Members. Ann Thorac Surg 2018.
8. Wu C, Zhao C, Yang Y, et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol. 2015;10:778–83.
9. Liu M, He WX, Song N, et al. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg. 2016;50:909–13.
10. Park E, Ahn S, Kim H, et al. Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Lepidic Nodules. J Thorac Oncol. 2018;13:778–83.
11. Shimada Y, Saji H, Otani K, et al. Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions. Lung Cancer. 2015;88:174–80.
12. Hattori A, Matsunaga T, Takamochi K, et al. Radiological classification of multiple lung cancers and the prognostic impact based on the presence of a ground glass opacity component on thin section computed tomography. Lung Cancer. 2017;113:7–13.
13. Sobin LH, Gospodarowicz MK, Wittekind C. editors. TNM classification of malignant tumours, 7th edition. Wiley-Blackwell; 2009.
14. Gu B, Burt BM, Merritt RE, et al. A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease. Ann Thorac Surg. 2013;96:411–8.
15. Gao RW, Berry MF, Kunder CA, et al. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2017;154:2092–9.
16. Bongiolatti S, Corzani R, Borgianni S, et al. Long-term results after surgical treatment of the dominant lung adenocarcinoma associated with ground-glass opacities. J Thorac Dis. 2018;10:4838-48.
17. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol. 2000;73:1252–59.
18. Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol. 2000;174:763–8.
19. Kobayashi Y, Fukui T, Ito S, et al. How long should small lung lesions of ground-glass opacity be followed? J Thorac Oncol. 2013;8:309–14.

20. Suh YJ, Lee HJ, Kim YJ, et al. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study. Lung Cancer. 2018;123:52–9.

### Tables

**Table 1. Patient characteristics**

|                      | Multiple (n=34) | Single (n=17) | Pure GGN (n=40) | Part Solid (n=40) |
|----------------------|-----------------|---------------|------------------|-------------------|
| Patients, n          | 34              | 17            | 40               |                   |
| Age, (years)         | 73.7±7.9        | 65.0±11.2     | 71.3±13.0        |                   |
| Gender, male/female  | 18/16           | 8/9           | 22/18            |                   |
| Previous cancer history, Yes (%) | 3 (9)    | 4 (24)        | 11 (28)          |                   |
| Surgical procedure, n|                 |               |                   |                   |
| Wedge resection      | 7 (20)          | 10 (59)       | 5 (12.5)         |                   |
| Segmentectomy        | 0               | 0             | 3 (7.5)          |                   |
| Lobectomy            | 19 (37)         | 7 (41)        | 32 (80)          |                   |
| Combination           | 8 (23)          | 0             | 0                |                   |
| Chemotherapy, n      |                 |               |                   |                   |
| None                 | 27 (79)         | 17 (100)      | 31 (77.5)        |                   |
| UFT                  | 6 (18)          | 0             | 9 (22.5)         |                   |
| Cisplatin based      |                 |               |                   |                   |
| chemotherapy         | 1 (3)           | 0             | 0                |                   |
| Dominant Tumor Size  |                 |               |                   |                   |
| (mm)                 | 23.7±13.9       | 10.9±4.6      | 19.4±7.9         |                   |
| pStage Ia, n         | 24 (70)         | 17 (100)      | 35 (87.5)        |                   |
| pStage Ib, n         | 6 (18)          | 0             | 4 (10)           |                   |
| pStage IIa, n        | 4 (12)          | 0             | 1 (2.5)          |                   |
| pStage IIb, n        | 0               | 0             | 0                |                   |

Values are means ± standard deviations or number (percentage). GGNs; ground glass nodules, UFT; tegafur-uracil.
Table 2. The results of postoperative surveillance

|                | Multiple | Single |
|----------------|----------|--------|
|                | Pure GGN | Part Solid | Solid |
| Recurrent patients, n | 2 (6) | 0 | 3 (7) | 13 (19) |
| EGFR (+), n      | 2 (100) | 0 | 1 (33) | 8 (62) |
| EGFR (-), n      | 0 | 0 | 1 (33) | 2 (15) |
| Unknown, n       | 0 | 0 | 1 (33) | 3 (23) |

Survival

|                | 5-year overall survival, % | 5-year disease-free survival, % |
|----------------|-----------------------------|----------------------------------|
|                | 88.2                        | 94.1                             |
|                | 93.9                        | 100                              |

|                | 90.0                        | 92.2                             |
|                | 74.3                        | 79.3                             |

Values are the number (percentage) or percentage. GGNs; ground glass nodules, EGFR; epidermal growth factor receptor.
## Table 3. Characteristics of patients with multiple GGNs

|                             | Multiple (N=34) |
|-----------------------------|----------------|
|                             | Pure GGN       | Part Solid     |
| Patients, n                 | 5              | 20             |
| Dominant Tumor Size (mm)    | 8.6±4.6        | 21.7±11.6      |
| Nondominant GGN             |                |                |
| Largest GGN size (mm)       | 8.1±1.8        | 8.2±5.2        |
| Number, n (range per patient) | 8 (1-2)      | 38 (1-7)       |
| Location per GGN            |                |                |
| Ipsilateral lung            |                |                |
| Same lobe, n                | 2 (25)         | 7 (18)         |
| Different lobe, n           | 2 (25)         | 12 (32)        |
| Contralateral lung, n       | 4 (50)         | 19 (50)        |
| Unresected GGN, n           | 5              | 22             |
| Patients, n                 | 3              | 14             |
| Patients with unresected GGN that grew, n | 0 | 7 |
| Patients with intervention for unresected GGN, n | 0 | 2 |
| Stereotactic radiotherapy, n | 0             | 1              |
| Surgical resection, n       | 0              | 1              |
| C/T ratio                   |                |                |
| =0, n                       | 5 (100)        | 19 (86)        |
| 0 < C/T ratio <0.5, n       | 0              | 3 (14)         |

Values are the mean ± standard deviation, number (percentage) or number (range per patient). GGNs: ground glass nodules.
Table 4. Characteristics of patients with GGN progression.

|                               | Unresected GGN () |   | P=   |
|-------------------------------|-------------------|---|------|
|                               | Progression       | No progression |      |
| N=10                          | N=14              |   |      |
| Age, (years)                  | 72.9±8.1          | 72.9±9.1       | 0.9656|
| Gender, male/female           | 5/5               | 5/9           | >0.9999|
| Dominant Tumor Size           | 28.4±12.7         | 20.9±14.5      | 0.158 |
| Smoking status (Pack-year)    | 19.4±21.9         | 8.3±13.7       | 0.328 |
| Unresected GGN                | 20                | 18            |      |
| Mean GGN size                 | 10.3±5.2          | 6.5±4.3        | 0.0004|
| Largest GGN size              | 12.4±6.4          | 7.2±4.6        | 0.0681|
| Survival                      |                   |               |      |
| 5-year overall survival, %    | 80                | 92.9          | 0.387 |

Values are the mean ± standard deviation, number or percentage. GGNs; ground glass nodules.
All patients surgically treated for the dominant tumor of lung from January 2009 to December 2013
n=330

Adenocarcinoma
n=233

Screening object
n=209

Multiple GGNs
n=39

Excluded due to loss to 5 years follow up (n=5)

Single
n=168
Figure 1
A flow diagram of the present study. GGNs; ground glass nodules, SCC; squamous cell carcinoma, AAH; atypical adenomatous hyperplasia.
Figure 2
The Kaplan-Meier analysis of the survival of patients with multiple and single lesions. (A) Single: 81.8% vs.
Multiple: 88.2%. When classified for each DT and compared (B) pure GGN, 94.1% vs. multiple GGN (pure), 100%; (C) part solid, 90% vs. multiple GGN (part), 90%; (D) Solid, 74.3% vs. multiple GGN (solid), 77.8%. GGNs; ground glass nodules, OS: overall survival.
Figure 3

Disease-free survival curves of patients with multiple and single lesions. (A) single vs. multiple, (B) pure GGN vs. multiple GGN (pure), (C) part solid vs. multiple GGN (part), (D) solid vs. multiple GGN (solid). GGNs; ground glass nodules, DFS; disease free survival.
Figure 4
A flow diagram of the patients with unresected GGN. GGNs; ground glass nodules.
Figure 5

(A) The transition in the size of 38 unresected GGNs on CT. (B) Comparison of the tumor diameter before surgery between lesions with and without growth. The preoperative tumor size of GGNs was significantly larger in comparison to tumors that did not grow in size (mean size, 11.7±5.8 mm vs. 6.9±3.8 mm, P = 0.0003). GGNs; ground glass nodules.
